文献速递神经肿瘤

激动型OX40免疫治疗改善胶质瘤荷瘤小鼠生存并与表达GM-CSF的受照射肿瘤细胞疫苗互补

Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
PubMed 文献 · Neuro Oncol · 2018-01-01

在GL261胶质瘤小鼠模型中,激动型抗OX40单克隆抗体联合表达GM-CSF的受照射肿瘤细胞疫苗(GVAX)较对照延长生存14天(中位生存36天 vs 22天,P<0.00005),并增强全身Th1抗肿瘤免疫、改善脑内CD8+/FoxP3+ T细胞比例、逆转颅内T细胞耗竭。

要点

  • GVAX联合全身激动型抗OX40单抗较对照延长生存14天(中位36天 vs 22天,P<0.00005)
  • 联合治疗显著增强全身Th1抗肿瘤免疫,脑内Th1 CD4+ T细胞比例升高、Th2比例降低
  • 疫苗改善脑内CD8+/FoxP3+ T细胞比例,联合治疗降低PD-1与TIM-3、PD-1与LAG-3共表达

核心结论

  • 激动型抗OX40免疫治疗对颅内胶质瘤有活性,并与GVAX有协同作用。
  • 疫苗接种与抗OX40免疫治疗在机制上互补,尤其在胶质瘤微环境中。

研究设计与样本

  • 将GL261肿瘤细胞植入同系小鼠右侧额叶,分入对照、激动型抗OX40单克隆抗体、皮下注射表达GM-CSF的受照射GL261细胞疫苗(GVAX)及疫苗联合激动型抗OX40治疗组,随访生存。
  • 第18天取脾细胞行酶联免疫斑点分析,取脑组织行免疫组化及流式细胞术分析浸润淋巴细胞。

主要发现

  • GVAX联合全身激动型抗OX40单克隆抗体较对照延长生存14天(中位生存36天 vs 22天,P<0.00005)。
  • 联合治疗显著增强全身Th1抗肿瘤免疫。
  • 脑内联合治疗提高Th1 CD4+ T淋巴细胞百分比并降低Th2百分比。
  • 脑内疫苗提高CD8+与FoxP3+ T淋巴细胞比值。
  • 联合治疗逆转颅内T淋巴细胞耗竭,降低PD-1与TIM-3及PD-1与LAG-3的共表达。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioma immunotherapy is an active area of clinical investigation. Glioma-associated immunosuppression remains an obstacle to efficacious immunotherapy, and combination approaches are likely necessary for durable success. OX40 is a member of the tumor necrosis factor receptor superfamily that is upregulated on activated lymphocytes, ligation of which results in enhanced activity and may be active against cancer. We sought to confirm the efficacy of agonist anti-OX40 immunotherapy against glioma and hypothesized that it is complementary with irradiated whole tumor cell vaccination. METHODS: GL261 tumor cells were implanted into the right frontal lobes of syngeneic mice, which were then treated with controls, agonist anti-OX40 monoclonal antibody, vaccination with subcutaneous injection of irradiated granulocyte macrophage colony stimulating factor (GM-CSF)-expressing GL261 cells (GVAX), or vaccination + agonist anti-OX40 therapy. Animals were followed for survival. On day 18, splenocytes were harvested for enzyme-linked immunosorbent spot analyses and brains were harvested for immunohistochemistry and flow cytometry analyses of infiltrating lymphocytes. RESULTS: Combination immunotherapy with GVAX and systemic agonist anti-OX40 monoclonal antibody improved survival by 14 days over controls (median survival 36 vs 22 days, P < 0.00005). Systemically, T helper cell type 1 (Th1) antitumor immunity was enhanced significantly by combination therapy. In the brain, combination immunotherapy increased the percentage of Th1 CD4+ T lymphocytes and reduced the fraction that were Th2. In the brain, vaccination improved the ratio of CD8+ to FoxP3+ T lymphocytes, while combination immunotherapy reversed intracranial T-lymphocyte exhaustion, reducing their coexpression of programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) as well as PD-1 and lymphocyte-activation gene 3 (LAG-3). CONCLUSIONS: Anti-OX40 immunotherapy is active against intracranial glioma and synergizes with GVAX. Vaccination and anti-OX40 immunotherapy are mechanistically complementary, particularly in the glioma microenvironment.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Jahan N, Talat H, Curry WT, et al. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells. Neuro Oncol. 2018. PMID: 29016879. doi:10.1093/neuonc/nox125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。